Hualan Vac(301207)2024-10-29 10:08Financial Performance - The company's revenue for Q3 2024 was ¥921,834,062.89, representing a decrease of 41.23% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2024 was ¥242,085,290.80, down 53.58% year-over-year[3]. - The basic earnings per share for Q3 2024 was ¥0.4042, a decline of 53.49% compared to the previous year[3]. - Total operating revenue for the current period is ¥957,363,018.62, a decrease of 44.4% compared to ¥1,718,267,831.09 in the previous period[20]. - Net profit for the current period is ¥267,359,727.86, a decrease of 57.5% compared to ¥629,714,837.48 in the previous period[21]. - Operating profit for the current period is ¥305,871,419.40, down 58.6% from ¥737,508,632.46 in the previous period[21]. - Basic earnings per share for the current period is ¥0.4463, down from ¥1.0495 in the previous period[22]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥7,641,648,782.70, a decrease of 4.42% from the end of the previous year[3]. - The total current assets decreased from 5,226,815,305.37 CNY at the beginning of the period to 4,631,880,229.62 CNY at the end of the period, representing a decline of approximately 11.4%[17]. - Total liabilities decreased from 1,732,226,370.79 CNY to 1,547,467,594.35 CNY, a reduction of approximately 10.7%[18]. - The company's total assets decreased from 7,995,318,297.21 CNY to 7,641,648,782.70 CNY, reflecting a decline of about 4.4%[18]. - The company's retained earnings decreased from 2,461,743,479.87 CNY to 2,369,094,207.73 CNY, a decrease of approximately 3.8%[19]. Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥350,644,555.60, down 28.24% year-over-year[3]. - Cash flow from operating activities for the current period is ¥350,644,555.60, a decrease of 28.3% compared to ¥488,668,014.32 in the previous period[23]. - The net cash flow from investing activities was -¥33,805,690.23, a 94.25% improvement from the previous period[8]. - The net cash flow from investing activities was -33,805,690.23 CNY, compared to -588,359,444.13 CNY in the previous period[24]. - The net increase in cash and cash equivalents was -109,728,909.46 CNY, compared to -224,261,096.50 CNY in the previous period[24]. - The ending balance of cash and cash equivalents was 531,251,202.49 CNY, up from 600,041,864.54 CNY at the beginning of the period[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,177[10]. - The largest shareholder, Hualan Biological Engineering, holds 67.38% of the shares, totaling 405,000,000 shares[10]. - The second-largest shareholder, Cyber Creator Limited, holds 8.98% of the shares, totaling 54,000,000 shares[10]. - The third-largest shareholder, Henan Huaying Enterprise Management Consulting Partnership, holds 4.99% of the shares, totaling 30,000,714 shares[10]. - The company has a total of 378,000 restricted shares due to executive lock-up[14]. - The report indicates that there are no preferred shareholders with voting rights[10]. - The top ten shareholders account for a significant portion of the total shareholding, with the largest three holding over 80% combined[10]. - The company has not disclosed any other relationships among the top ten shareholders, except for the relationship between Hualan Biological Engineering and Cyber Creator Limited[11]. - The report does not indicate any changes in the number of shares held by the top ten shareholders due to margin trading[12]. - The company has not issued any new shares during the reporting period[14]. Operational Adjustments - The company adjusted the prices of its quadrivalent influenza vaccines effective June 5, 2024, with adult prefilled 0.5ml at 88 CNY per dose, adult vial 0.5ml at 85 CNY per vial, and children's prefilled 0.25ml at 128 CNY per dose[15]. - The company aims to stimulate market demand for influenza vaccines through price adjustments, despite an expected short-term negative impact on sales revenue[15]. - The company plans to enhance internal cost control and improve sales volume to mitigate the pressure from price reductions[15]. - Research and development expenses for the current period are ¥80,510,272.88, an increase of 12.8% compared to ¥71,494,795.96 in the previous period[20]. - Sales expenses for the current period are ¥411,829,871.25, down 42% from ¥709,393,184.19 in the previous period[20]. - Tax expenses for the current period are ¥38,541,370.30, a decrease of 63.4% compared to ¥105,212,998.05 in the previous period[21]. Inventory Management - The company reported a significant increase in inventory, with a 40.56% rise to ¥243,832,814.78 compared to the beginning of the year[6]. - Inventory increased from 173,470,942.08 CNY to 243,832,814.78 CNY, marking an increase of about 40.5%[17].